Bundle in the Bronx: Impact of a Transition-of-Care Outpatient Parenteral Antibiotic Therapy Bundle on All-Cause 30-Day Hospital Readmissions

Abstract Background A streamlined transition from inpatient to outpatient care can decrease 30-day readmissions. Outpatient parenteral antibiotic therapy (OPAT) programs have not reduced readmissions; an OPAT bundle has been suggested to improve outcomes. We implemented a transition-of-care (TOC) OPAT bundle and assessed the effects on all-cause, 30-day hospital readmission. Methods Retrospectively, patients receiving postdischarge intravenous antibiotics were evaluated before and after implementation of a TOC-OPAT program in Bronx, New York, between July, 2015 and February, 2016. Pearson’s χ2 test was used to compare 30-day readmissions between groups, and logistic regression was used to adjust for covariates. Time from discharge to readmission was analyzed to assess readmission risk, using log-rank test to compare survival curves and Cox proportional hazards model to adjust for covariates. Secondary outcomes, 30-day emergency department (ED) visits, and mortality were analyzed similarly. Results Compared with previous standard care (n = 184), the TOC-OPAT group (n = 146) had significantly lower 30-day readmissions before (13.0% vs 26.1%, P < .01) and after adjustment for covariates (odds ratio [OR] = 0.51; 95% confidence interval [CI], 0.27–0.94; P = .03). In time-dependent analyses, TOC-OPAT patients were at significantly lower risk for readmission (log-rank test, P < .01; hazard ratio = 0.56; 95% CI, 0.32–0.97; P = .04). Propensity-matched sensitivity analysis showed lower readmissions in the TOC-OPAT group (13.6% vs 24.6%, P = .04), which was attenuated after adjustment (OR = 0.51; 95% CI, 0.25–1.05; P = .07). Mortality and ED visits were similar in both groups. Conclusions Our TOC-OPAT patients had reduced 30-day readmissions compared with the previous standard of care. An effective TOC-OPAT bundle can successfully improve patient outcomes in an economically disadvantaged area.

[1]  E. Jaqua,et al.  The Patient Protection and Affordable Care Act (PPACA) , 2019, Journal of Nursing and Healthcare Management.

[2]  S. Bleasdale,et al.  Predictors of Hospital Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy , 2016, Pharmacotherapy.

[3]  N. Daneman,et al.  Patient Characteristics and Outcomes of Outpatient Parenteral Antimicrobial Therapy: A Retrospective Study , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[4]  G. Parameswaran,et al.  Outcomes and Pharmacoeconomic Analysis of a Home Intravenous Antibiotic Infusion Program in Veterans. , 2015, Clinical therapeutics.

[5]  Rupak Datta,et al.  Impact of Hospital Population Case-Mix, Including Poverty, on Hospital All-Cause and Infection-Related 30-Day Readmission Rates. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  G. Tomlinson,et al.  Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  David M Kent,et al.  Prediction model for 30-day hospital readmissions among patients discharged receiving outpatient parenteral antibiotic therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Amy S Nowacki,et al.  Association of laboratory test result availability and rehospitalizations in an outpatient parenteral antimicrobial therapy programme. , 2014, The Journal of antimicrobial chemotherapy.

[9]  Lawrence P. Martinelli,et al.  Infectious diseases specialty intervention is associated with decreased mortality and lower healthcare costs. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  W. Bilker,et al.  The Impact of an Infectious Diseases Transition Service on the Care of Outpatients on Parenteral Antimicrobial Therapy , 2013, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[11]  G. Allison,et al.  Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Dresser,et al.  Outpatient parenteral antimicrobial therapy for surgery patients: A comparison with previous standard of care. , 2013, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[13]  W. Barsoum,et al.  Patients with Prosthetic Joint Infection on IV Antibiotics are at High Risk for Readmission , 2009, Clinical orthopaedics and related research.

[14]  Stephen A. Martin,et al.  A Reengineered Hospital Discharge Program to Decrease Rehospitalization , 2009, Annals of Internal Medicine.

[15]  Peter C. Austin,et al.  Effect of discharge summary availability during post-discharge visits on hospital readmission , 2002, Journal of General Internal Medicine.

[16]  Sung-joon Min,et al.  The care transitions intervention: results of a randomized controlled trial. , 2006, Archives of internal medicine.

[17]  John S. Bradley,et al.  Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy , 2004 .

[18]  Donald R Graham,et al.  Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Kerr,et al.  The impact of follow-up telephone calls to patients after hospitalization. , 2002, The American journal of medicine.

[20]  E. W. Johnson,et al.  Out-patient parenteral antibiotic therapy (OPAT): clinical outcomes and adverse events. , 2001, Hawaii medical journal.

[21]  B A Cunha,et al.  Antibiotic side effects. , 2001, The Medical clinics of North America.

[22]  J. Kateiva,et al.  Financial impact of a home intravenous antibiotic program on a medicare managed care program. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  H. Fraimow,et al.  Adverse effects of outpatient parenteral antibiotic therapy. , 1999, The American journal of medicine.

[24]  D. N. Williams,et al.  Practice guidelines for community-based parenteral anti-infective therapy. ISDA Practice Guidelines Committee. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  M. Grayson,et al.  Home intravenous antibiotic therapy: A safe and effective alternative to inpatient care , 1995, The Medical journal of Australia.

[26]  W. Balinsky,et al.  Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. , 1989, The American journal of medicine.

[27]  D. Gilbert,et al.  Feasibility of outpatient self-administration of parenteral antibiotics. , 1978, The Western journal of medicine.

[28]  R. Rucker,et al.  Outpatient intravenous medications in the management of cystic fibrosis. , 1974, Pediatrics.